Research Tracker›Biomarker Atlas›Marker Pages›C16 Acylcarnitine (palmitoylcarnitine)

C16 Acylcarnitine (palmitoylcarnitine): biomarker evidence

C16 Acylcarnitine (palmitoylcarnitine) appears in 1 entry of the OSMF biomarker atlas, covering ME/CFS. Across those entries it is reduced in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

ME/CFS

Where C16 Acylcarnitine (palmitoylcarnitine) is reported

Also listed as: Long-chain acylcarnitine

ConditionDirectionCompared againstAssociated symptomsSource
ME/CFS↓ reducedhealthy controlsImpaired β-oxidationJinushi et al. 2023 (meta-analysis of pooled serum acylcarnitine; C16 not reported separately)

Frequently asked questions

In which conditions is C16 Acylcarnitine (palmitoylcarnitine) altered?

In the OSMF atlas C16 Acylcarnitine (palmitoylcarnitine) is reported in ME/CFS. It is reduced in 1 across 1 entries.

Is there a standard clinical test for C16 Acylcarnitine (palmitoylcarnitine)?

The atlas entries for C16 Acylcarnitine (palmitoylcarnitine) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal C16 Acylcarnitine (palmitoylcarnitine) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). C16 Acylcarnitine (palmitoylcarnitine) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/markers/c16-acylcarnitine-palmitoylcarnitine.html

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.